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Infectious disease is a major cause of morbidity and mortality, and 
is responsible for >50% of intensive care unit (ICU) admissions 
globally. [1] Attempts to improve outcomes of patients with sepsis 
include better definitions of sepsis, identifying high-risk patient 
subgroups, and allocation of therapies to patient subgroups that are 
most likely to benefit from these therapies.
Lactate is a product of the metabolism of glucose during glycolysis. 
It results from the conversion of pyruvate to lactate by the action 
of lactate dehydrogenase. During sepsis, an increased blood lactate 
concentration, ‘hyperlactataemia’, is seen during tissue dysoxia where 
sufficient oxygen is not available, as in hypoperfusion states, or not 
utilisable, when mitochondrial oxidation is impaired.[2] It may also 
result from overstimulation of aerobic glycolysis by inflammatory 
mediators leading to glycolytic flux that exceeds the capacity 
of enzymes to convert pyruvate to acetyl coenzyme A. Finally, 
hyperlactataemia may result from impaired lactate clearance rather 
than overproduction.[3]
In patients with sepsis and septic shock, hyperlactataemia is 
therefore common, being found in >50% of patients, and may be 
associated with increased morbidity and mortality.[4,5] In patients with 
severe sepsis and septic shock, hyperlactataemia may be associated 
with an increased risk of death independent of vasopressor need, 
especially if the initial lactate level is >4 mmol/L.[6,7]
The Third International Consensus Definitions for Sepsis and 
Septic Shock (Sepsis-3) were published in 2016 and included 
hyperlactataemia (serum lactate >2.0 mmol/L) as a mandatory 
component of the new definition of septic shock.[8] The rationale 
for this inclusion was that patients with both hypotension requiring 
inotropic support and hyperlactataemia represented a subgroup with 
significantly higher mortality than patients with either abnormality 
alone. Clinically, the addition of lactate as a mandatory marker in the 
new definition may alert the clinician to cellular and cardiovascular 
dysfunction that is not apparent from the need for inotropic support 
alone.[9]
These changes in the definitions of sepsis and septic shock have 
significant implications for the clinical care of patients with sepsis 
and for future research in these patients. Despite these definitions 
being derived from large international databases, much criticism 
still surrounds them. These data were collected mainly from high-
income countries (HICs) and lack adequate validation in scenarios 
outside these countries. The only study that the authors are aware of 
outside a HIC was conducted in Brazil.[10] While this study validated 
the use of hyperlactataemia in identifying a high-risk subset of 
patients with sepsis and hypotension requiring inotropic support, 
it suggested that a higher cut-off (>4.0 mmol/L) was optimal in 
their setting. It is therefore unknown whether the current Sepsis-3 
definition is applicable to all patient populations in low- and middle-
income countries (LMICs),[10] and specifically no studies have been 
performed in sub-Saharan Africa. The critical care data from the 
South African Surgical Outcomes Study indicated that significant 
differences exist between South African (SA) critical care patients 
and those in HICs: they were significantly younger, had a significantly 
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lower rate of ICU admission and underwent more urgent surgery 
than the European Surgical Outcomes Study patients. [11] A recent 
local publication[12] showed that the spectrum of surgical sepsis 
presenting to SA hospitals is different from that seen in HICs. Their 
patient cohort was much younger and generally presented with more 
advanced disease.
Objectives
There is both a lack of appropriate research in SA and evidence that 
regional differences in the applicability of the Sepsis-3 definition 
may exist. It is therefore essential that the definition of septic shock 
as proposed in Sepsis-3 is validated in the SA context prior to 
clinical application. Our objective was to evaluate whether the new 
Sepsis-3 definition of septic shock, and specifically the requirement 
for hyperlactataemia in addition to inotropic support, retained 
utility in the SA context. In particular, we aimed to assess whether 
hyperlactataemia identified a patient subgroup at significantly higher 
risk of death than those without hyperlactataemia, and if so, what the 
optimal cut-off point would be.
Methods
This study was a retrospective observational chart review of patients 
admitted to the ICU at King Edward VIII Hospital, an academic 
tertiary medical centre in Durban, SA. The study ICU is a 12-bed 
mixed medical/surgical ICU serving the province of KwaZulu-Natal.
The study protocol was approved by the University of KwaZulu-
Natal Biomedical Research Ethics Committee (ref. no. BE-457/17) 
and the provincial Department of Health (ref. no. HRKM 475/17).
Data collection
All data collected were obtained from patient files stored in the ICU. 
These files contained clinical and laboratory data necessary for the 
study, which had been collected as part of routine clinical care. Data 
collection started from the date of ethical approval backward until 
the calculated sample size was obtained. ICU files of consecutive 
patients admitted to the ICU were assessed for eligibility into the 
study. For the purpose of the study, ‘inotropic’ support was defined 
as use of either of the ‘inopressors’ adrenaline or noradrenaline. 
Pure vasopressors such as vasopressin or phenylephrine are not 
used in the study ICU, and the ‘pure’ inotrope dobutamine is not 
used in the unit in patients in septic shock. All adult patients 
admitted with hypotension requiring inotropic support, which was 
believed by the admitting intensivist to be infectious in aetiology 
(‘septic shock’ as per consensus definition prior to Sepsis-3), were 
eligible for inclusion. Children aged <18 years and patients who 
did not have lactate measured were excluded. Admission serum 
lactate, as measured by the GEM Premier 3000 blood gas machine 
(Instrumentation Laboratory, Werfen Group, Spain), was used for the 
purposes of this study.
Statistical analysis
Sample size was calculated using data from Sepsis-3 that reported 
a mortality rate of 54.0% in the hyperlactataemic and inotrope-
requiring subgroup, and 25.2% in the subgroup that required 
inotropic support but was not hyperlactataemic (data from the 
Pittsburgh Medical Centre).[8] These data were chosen because they 
best approximated the baseline mortality of patients with septic shock 
in the study ICU. The alpha value was set at 5% and the power at 90%, 
and a 2:1 ratio between patients with and without hyperlactataemia 
was chosen. The sample size using this methodology was estimated 
at 129. Preliminary data suggested a ratio closer to 3:1, so the sample 
size was increased to 170 to allow for uncertainty in this parameter. 
Statistical analysis was performed using SPSS Statistics for Windows, 
version 25.0 (IBM, USA), and R, version 3.5.1. Categorical variables 
were described as percentages and compared using the χ2 test or 
Fisher’s exact test, where appropriate. Continuous data were described 
using means and standard deviations when normally distributed 
and medians and interquartile ranges when the distribution was 
non-Gaussian. These data were compared using the independent-
samples t-test or the Mann-Whitney U-test, respectively. A receiver 
operating characteristic (ROC) curve was constructed for lactate. 
Optimal cut-off points were established for each of the variables 
by determining the point closest to the (0.1) corner in the ROC 
plane. Multivariable logistic regression analysis was performed using 
demographic variables that were significant (p<0.05) on univariate 
analysis, the admission sequential organ failure assessment (SOFA) 
score and serum lactate (as a continuous variable). Further analyses 
were performed where lactate as a continuous variable was replaced 
with lactate as a categorical variable using the cut-offs of 2.0 mmol/L 
(as per Sepsis-3) and the optimal cut-off point identified in the ROC 
analysis. This was intended as a more clinically applicable analysis, as 
the use of binary categorical variables is arguably more useful from a 
clinical point of view, while continuous variables may be preferable 
statistically. The diagnostic performance (in terms of ICU mortality) 
of the above cut-offs (2.0 mmol/L and the optimal cut-off on ROC 
analysis) was also evaluated in terms of sensitivity, specificity, positive 
predictive value, negative predictive value, positive likelihood ratio, 
negative likelihood ratio, number needed to diagnose and diagnostic 
accuracy. In addition, the performance of the two key lactate cut-
offs was compared using net reclassification improvement (NRI). 
For this purpose, mortality risk was stratified using the following 
categories: predicted mortality <25.0%, 25.0 - 49.9%, 50.0 - 74.9% 
and ≥75.0%, which were derived from the multivariable logistic 
regression analyses described above.
Results
A total of 170 adult patients with sepsis requiring inotropic support 
and who had an admission serum lactate result available were 
included in the study. The ICU mortality rate for the cohort was 
49.4% (84 patients). Most patients received adrenaline, with only 8 
(4.7%) receiving noradrenaline.
Table 1 highlights the demographic and outcome data for the 
cohort, as well as admission serum lactate data, and provides the 
univariate analyses for these factors and ICU mortality. Most patients 
were surgical (71.8%), with the most common source of sepsis being 
abdominal (55.9%), followed by pulmonary (25.9%).
ROC curve analysis for admission serum lactate and ICU mortality 
is shown in Fig. 1. The area under the curve was 0.612, standard error 
0.041 (95% confidence interval 0.527 - 0.696) (p=0.012). The optimal 
cut-off point was 4.5 mmol/L.
Table 2 shows the categorical univariate analyses for various cut-
offs for lactate for ICU mortality. The cut-offs for lactate were derived 
from the Sepsis-3 definition (>2.0 mmol/L) and other cut-offs 
explored in the literature (>3.0 or >4.0 mmol/L), as well as the optimal 
cut-off from the ROC curve analysis (>4.5 mmol/L). Using the cut-
off of 2.0 mmol/L, 126 patients (74.1%) were hyperlactataemic. 
ICU mortality was 52.4% for patients with an admission serum 
lactate level >2.0 mmol/L, as opposed to 40.9% for those with a 
level ≤2.0 mmol/L. The corresponding values for a lactate cut-off of 
4.5 mmol/L were 39.3% and 59.3%.
The results of the multivariable logistic regression analysis using 
lactate as continuous variable are shown in Table 3. The additional 
analyses with lactate as categorical variable (using the cut-offs of 
2.0 and 4.5 mmol/L) are shown below this in Table 3. Lactate as a 
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continuous variable and as a categorical variable with a cut-off of 
4.5 mmol/L remained independently associated with ICU mortality.
The diagnostic performance of lactate as a categorical variable 
with the key cut-offs of 2.0 mmol/L and 4.5 mmol/L is shown in 
Table 4.
The net reclassification improvement for a lactate cut-off of 
4.5 mmol/L v. 2.0 mmol/L was 5.0% for those with events (ICU 
mortality), while the NRI for those without events (ICU survival) was 
8.2%, giving a total NRI of 13.2% (p=0.104).
Table 1. Demographic data, outcomes and admission serum lactate
Entire cohort Survived Died p-value
Age, median (IQR) 42 (30.00 - 58.00) 38 (26.00 - 53.00) 48 (34.00 - 62.00) <0.001
Gender, n (%) 0.003
Female 94 (55.3) 38 (44.2) 56 (66.7)
Admission discipline, n (%) 0.144
Medicine 48 (28.2) 20 (23.3) 28 (33.3)
Surgery 122 (71.8) 66 (76.7) 56 (66.7)
Source of sepsis, n (%) 0.714
Abdominal 95 (55.9) 51 (59.3) 44 (52.4)
Bloodstream infection 3 (1.8) 2 (2.3) 1 (1.2)
Chest 44 (25.9) 20 (23.3) 24 (28.6)
CNS 4 (2.4) 1 (1.2) 3 (3.6)
Skin and soft tissue 24 (14.1) 12 (14.0) 12 (14.3)
Duration of ICU stay (days), median (IQR) 5 (3 - 7) 6 (4 - 8) 3 (2 - 6) <0.001
Duration of inotropic support (days), median (IQR)  3 (2 - 4) 3 (2 - 4) 3 (2 - 4) 0.925
Duration of ventilation (days), median (IQR) 4 (2 - 6) 4 (3 - 7) 3 (2 - 6) 0.072
SOFA (admission), median (IQR) 10 (8 - 12) 9 (7 - 11) 11 (9 - 12) 0.003
Renal replacement therapy in ICU, n (%)  24 (14.1) 13 (15.1) 11 (13.1) 0.705
Ventilation in ICU, n (%)  167 (98.2) 83 (96.5) 84 (100) 0.246
Admission serum lactate (mmol/L), median (IQR) 4.6 (2 - 7.5) 3.8 (1.9 - 6.8) 5.6 (2.6 - 8.2) 0.012
IQR = interquartile range; CNS = central nervous system; ICU = intensive care unit; SOFA = sequential organ failure assessment.
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Fig. 1. Receiver operating characteristic curve of serum lactate and intensive 
care unit mortality.
Table 2. Univariate analyses of lactate categorical variables for intensive care unit mortality
Lactate level (mmol/L) Entire cohort, n (%) Survived, n (%) Died, n (%) p-value OR (95% CI)
>2.0 126 (74.1) 60 (69.8) 66 (78.6) 0.190 1.59 (0.79 - 3.19)
>3.0 112 (65.9) 50 (58.1) 62 (73.8) 0.031 2.03 (1.06 - 3.88)
>4.0 93 (54.7) 40 (46.5) 53 (63.1) 0.030 1.97 (1.07 - 3.63)
>4.5 86 (50.6) 35 (40.7) 51 (60.7) 0.009 2.25 (1.22 - 4.16)
OR = odds ratio; CI = confidence interval.
Table 3. Multivariable analyses for intensive care unit 
mortality
  OR (95% CI) p-value
1 Age 1.04 (1.02 - 1.06) 0.001
Gender (female) 2.35 (1.19 - 4.67) 0.014
Lactate 1.13 (1.02 - 1.25) 0.019
SOFA 1.15 (1.02 - 1.30) 0.028
2 Age 1.03 (1.01 - 1.06) 0.001
Gender (female) 2.41 (1.22 - 4.73) 0.011
Lactate >2.0 mmol/L 1.35 (0.63 – 2.86) 0.439
SOFA 1.16 (1.03 - 1.31) 0.015
3 Age 1.04 (1.02 - 1.06) 0.001
Gender (female) 2.41 (1.22 - 4.78) 0.011
Lactate >4.5 mmol/L 2.26 (1.14 – 4.52) 0.020
SOFA 1.15 (1.01 - 1.29) 0.030
OR = odds ratio; CI = confidence interval; SOFA = sequential organ failure assessment.
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Discussion
For decades, hyperlactataemia has been shown to be associated 
with increased mortality in patients with shock, and in particular 
septic shock.[7,13] Lactate has been used as a marker of ‘cryptic’ shock, 
and lactate clearance has been used to guide resuscitation. [14-16] 
Recently the use of lactate to risk-stratify patients with sepsis, and 
sepsis-induced hypotension requiring inotropic support, has been 
advocated in the Sepsis-3 consensus definitions of sepsis and septic 
shock. EPIC II showed significant international differences in the 
prevalence of infections, types of infecting micro-organisms, and 
mortality rates in Eastern Europe compared with Western Europe, in 
Australia compared with Asia, and in Latin America compared with 
North America.[17,18] The present study is the first to evaluate the use 
of lactate to risk-stratify patients with sepsis-induced hypotension 
requiring inotropic support in sub-Saharan Africa.
The study population was young, with a median age of only 
42  years. This contrasts with most international ICU literature and 
illustrates the importance of validating international guidelines in the 
SA context.[11] While there was a preponderance of surgical patients 
and patients with intra-abdominal sepsis in the study, the cohort 
comprised a spectrum of patients, a significant number of whom 
had pneumonia and skin and soft-tissue infections.[12] As expected 
of a cohort of patients in septic shock, mortality was relatively high 
at 49.4%. This figure is in keeping with the median admission SOFA 
score of 10. The median ICU length of stay was relatively short at 
5 days, reflecting pressure on ICU beds in the study ICU.
The rationale for the addition of serum lactate to the definition 
of septic shock in Sepsis-3 was to allow for the differentiation of 
patients with sepsis-induced hypotension into high-risk and low-risk 
subgroups. As such, patients in the cohorts reported in Sepsis-3 who 
had hypotension requiring inotropic support and elevated serum 
lactate had higher mortality than those without elevated serum 
lactate. Patients without hyperlactataemia had hospital mortalities 
of 18.8%, 25.2%, and 30.1% in the three cohorts evaluated, and 
mortality rates increased to 35%, 42.3%, and 54%, respectively, in 
patients with a serum lactate level of >2.0 mmol/L.[8]
The objective of this study was to determine whether 
hyperlactataemia in patients with sepsis requiring inotropic support 
was also associated with increased mortality in the SA context. 
Neither the derivation nor validations cohorts for the Sepsis-3 
definitions appear to have included any patients from the African 
continent. As with the results reported in Sepsis-3, hyperlactataemia 
was associated with increased mortality in our study. While the 
mortality rate in our study was 40.9% in patients with a lactate level of 
≤2.0 mmol/L and 52.4% in those with a lactate level of >2.0 mmol/L, 
this difference did not reach statistical significance. In our study the 
optimal cut-off was 4.5 mmol/L, which is similar to the optimal cut-
off of 4.0 mmol/L in a Brazilian study. At a cut-off of 4.5 mmol/L 
there was a clear, statistically significant difference in mortality 
between patients without hyperlactataemia (39.3%) and those with 
hyperlactataemia (59.3%) (p=0.009).
It is noteworthy that the SA and Brazilian cohorts (median age 
42 years and 52 years, respectively) were younger than the Sepsis-3 
cohorts (>60 years).[8,10] A recent publication compared the prognostic 
value of hyperlactataemia in predicting mortality between elderly 
(≥65 years) and non-elderly (<65 years) patients with sepsis, and 
showed that elderly non-survivors had a 1 mmol/L lower serum 
lactate level than non-elderly non-survivors.[19] One explanation is 
that elderly patients have different physiology and multiple systemic 
disorders compared with younger adults. Elderly patients with sepsis 
had a lower temperature, lower heart rate and higher mean arterial 
pressure, which may alter their lactate production and metabolism. [19] 
Other explanations as to why patients with sepsis from HICs had 
lower lactate levels than patients from LMICs include the use of early 
protocolised sepsis management and resuscitation in HICs that relies 
on complex invasive technology that may not be widely available 
in resource-limited countries.[20] This early sepsis recognition and 
resuscitation can augment lactate clearance, which may be reflected 
as lower lactate levels in these patients on ICU admission. The need 
for a higher lactate threshold in our study could also have been due 
to the predominant use of adrenaline in the study ICU, which may 
theoretically lead to an increase in lactate levels.[21] While our study 
had a predominance of patients with abdominal sepsis, both the 
Brazilian and Sepsis-3 cohorts had a predominance of patients with 
pneumonia. This difference has been observed in previous studies, 
where elderly patients with sepsis were more likely to have respiratory 
tract infection, while non-elderly patients were more likely to have 
abdominal and soft-tissue sepsis.[19,22]
While the present study broadly validates the principle that 
hyperlactataemia identifies a particularly high-risk subset of patients 
with sepsis who require inotropic/vasopressor support, the concern 
remains that the use of lactate measurement in this setting may 
impose unnecessary financial or logistical costs, or that it may 
simply not be available in certain settings. While the study ICU is 
in a middle-income country, it is comparatively well-resourced and 
the availability of lactate measurements cannot be taken for granted 
in other middle- and lower-income settings. For this reason, further 
research is required to evaluate the utility of clinical parameters that 
may provide equivalent risk-stratification benefits.
Study limitations
This study has several potential limitations. The retrospective design 
could have led to bias. The data were derived from a single ICU, and 
may not be generalisable. The study ICU is a busy referral centre, 
however, and is likely to be representative of the realities of critical 
care in at least the state sector in SA. It is the only study of its kind 
from Africa and is therefore the most representative study available 
for the continent. The primary outcome was ICU mortality as 
opposed to hospital mortality, which is the most common outcome 
used in similar studies. The choice of ICU mortality was due to 
practical difficulties in establishing hospital mortality in the study 
population, and while this does not invalidate the findings of this 
Table 4. Diagnostic performance of lactate as a categorical variable
Lactate 
(mmol/L)
Sensitivity, 
% (95% CI)
Specificity, 
% (95% CI)
PPV, % 
(95% CI)
NPV, % 
(95% CI)
PLR  
(95% CI)
NLR  
(95% CI) NND
Diagnostic accuracy,  
% (95% CI)
>2.0 78.6 (68.3 - 
86.8)
30.2 (20.8 - 
41.1)
52.4 (43.3 - 
61.4)
59.1 (43.3 - 
73.7)
1.13 (0.94 - 
1.35)
0.71 (0.42 - 
1.19)
11.4 54.2 (46.3 - 61.8)
>4.5 60.7 (49.5 - 
71.2)
59.3 (48.2 - 
69.8)
59.3 (48.2 - 
69.8)
60.7 (49.5 - 
71.2)
1.49 (1.10 - 
2.03)
0.66 (0.48 - 
0.91)
5 60.6 (52.2 - 67.4)
PPV = positive predictive value; NPV = negative predictive value; PLR = positive likelihood ratio; NLR = negative likelihood ratio; NND = number needed to diagnose; CI = confidence 
interval.
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study, it does potentially confound direct comparison with other 
studies that used hospital mortality as their primary endpoint. The 
use of adrenaline as the predominant inotrope/vasopressor may have 
led to an increase in serum lactate levels. Noradrenaline is not freely 
available in SA, further illustrating the need for studies that reflect 
practice in different settings.
Conclusions
In our study, hyperlactataemia was associated with increased 
mortality. However, a lactate level >2.0 mmol/L, as proposed in 
Sepsis-3, did not reach statistical significance. A higher cut-off of 
>4.5 mmol/L should be used in the SA context (and potentially in 
other LMICs) to identify patients with sepsis-induced hypotension 
requiring inotropic support who are at increased risk of death.
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